X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ALKEM LABORATORIES NATCO PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 16.7 - - View Chart
P/BV x 18.0 7.0 257.3% View Chart
Dividend Yield % 0.6 0.6 102.6%  

Financials

 NATCO PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ALKEM LABORATORIES
Mar-16
NATCO PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8771,589 55.2%   
Low Rs4241,232 34.4%   
Sales per share (Unadj.) Rs223.4417.5 53.5%  
Earnings per share (Unadj.) Rs31.156.3 55.2%  
Cash flow per share (Unadj.) Rs40.364.7 62.2%  
Dividends per share (Unadj.) Rs5.0012.70 39.4%  
Dividend yield (eoy) %0.80.9 85.4%  
Book value per share (Unadj.) Rs219.5292.9 74.9%  
Shares outstanding (eoy) m33.07119.57 27.7%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.4 86.1%   
Avg P/E ratio x20.925.1 83.5%  
P/CF ratio (eoy) x16.121.8 74.1%  
Price / Book Value ratio x3.04.8 61.5%  
Dividend payout %16.122.6 71.3%   
Avg Mkt Cap Rs m21,504168,653 12.8%   
No. of employees `000NANA-   
Total wages/salary Rs m1,1289,171 12.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,38949,915 14.8%  
Other income Rs m1671,645 10.2%   
Total revenues Rs m7,55651,561 14.7%   
Gross profit Rs m1,7938,482 21.1%  
Depreciation Rs m3041,006 30.3%   
Interest Rs m366671 54.6%   
Profit before tax Rs m1,2908,451 15.3%   
Minority Interest Rs m46-114 -40.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3091,606 19.2%   
Profit after tax Rs m1,0276,731 15.3%  
Gross profit margin %24.317.0 142.8%  
Effective tax rate %23.919.0 125.9%   
Net profit margin %13.913.5 103.1%  
BALANCE SHEET DATA
Current assets Rs m3,68127,062 13.6%   
Current liabilities Rs m3,12315,324 20.4%   
Net working cap to sales %7.623.5 32.1%  
Current ratio x1.21.8 66.8%  
Inventory Days Days8967 134.5%  
Debtors Days Days5941 142.2%  
Net fixed assets Rs m7,68512,610 60.9%   
Share capital Rs m331239 138.3%   
"Free" reserves Rs m6,67034,490 19.3%   
Net worth Rs m7,25935,027 20.7%   
Long term debt Rs m9551,212 78.8%   
Total assets Rs m11,95754,387 22.0%  
Interest coverage x4.513.6 33.2%   
Debt to equity ratio x0.10 380.3%  
Sales to assets ratio x0.60.9 67.3%   
Return on assets %11.713.6 85.6%  
Return on equity %14.219.2 73.7%  
Return on capital %20.724.9 83.4%  
Exports to sales %39.412.9 304.0%   
Imports to sales %5.73.1 184.7%   
Exports (fob) Rs m2,9086,461 45.0%   
Imports (cif) Rs m4211,540 27.3%   
Fx inflow Rs m3,4456,563 52.5%   
Fx outflow Rs m7033,012 23.3%   
Net fx Rs m2,7433,552 77.2%   
CASH FLOW
From Operations Rs m1,4407,259 19.8%  
From Investments Rs m-1,0891,864 -58.4%  
From Financial Activity Rs m-353-9,273 3.8%  
Net Cashflow Rs m-1-150 1.0%  

Share Holding

Indian Promoters % 52.0 66.9 77.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 33.1 23.7%  
FIIs % 16.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 0.0 -  
Shareholders   25,395 68,381 37.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  FULFORD INDIA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 24, 2018 09:27 AM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - WYETH LTD COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS